Califf's Ethics Letter Lists Conflicts He Averted
This article was originally published in The Tan Sheet
Executive Summary
The waiting periods that followed the end of the FDA commissioner nominee’s affiliations with several pharma firms already have expired.
You may also be interested in...
Learning To Drive The ‘Chariot’: FDA Deputy Califf’s New Role
Renowned clinical trialist and cardiologist will become deputy commissioner for medical products and tobacco, a complicated and challenging position.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.